Establishment Labs (NASDAQ:ESTA) Trading 6% Higher - What's Next?

Shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA - Get Free Report) rose 6% on Wednesday . The stock traded as high as $37.72 and last traded at $37.90. Approximately 171,663 shares changed hands during mid-day trading, a decline of 64% from the average daily volume of 471,176 shares. The stock had previously closed at $35.76.

Analyst Ratings Changes

ESTA has been the subject of several research reports. Stephens reiterated an "overweight" rating and issued a $52.00 target price on shares of Establishment Labs in a report on Thursday, March 6th. Needham & Company LLC reaffirmed a "buy" rating and issued a $48.00 price objective on shares of Establishment Labs in a research report on Friday, June 13th. Wall Street Zen raised Establishment Labs from a "sell" rating to a "hold" rating in a report on Saturday, June 14th. Finally, BTIG Research began coverage on Establishment Labs in a report on Friday, May 16th. They issued a "buy" rating and a $62.00 price objective on the stock. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat, Establishment Labs presently has an average rating of "Moderate Buy" and an average price target of $52.40.

Establishment Labs Stock Up 0.2%

The business has a fifty day moving average price of $35.37 and a two-hundred day moving average price of $36.85. The company has a debt-to-equity ratio of 5.72, a current ratio of 3.36 and a quick ratio of 2.05. The firm has a market capitalization of $1.18 billion, a price-to-earnings ratio of -13.20 and a beta of 0.74.

Establishment Labs (NASDAQ:ESTA - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported ($0.70) EPS for the quarter, topping analysts' consensus estimates of ($0.83) by $0.13. Establishment Labs had a negative return on equity of 196.25% and a negative net margin of 52.34%. The firm had revenue of $41.38 million for the quarter, compared to the consensus estimate of $41.15 million. During the same quarter in the prior year, the business earned ($0.58) earnings per share. The company's revenue was up 11.3% compared to the same quarter last year. On average, equities analysts expect that Establishment Labs Holdings Inc. will post -2.41 earnings per share for the current year.

Institutional Trading of Establishment Labs

A number of hedge funds have recently modified their holdings of the stock. Brown Advisory Inc. boosted its stake in shares of Establishment Labs by 23.1% in the fourth quarter. Brown Advisory Inc. now owns 2,338,369 shares of the company's stock worth $107,729,000 after buying an additional 438,057 shares during the last quarter. Capital Research Global Investors boosted its stake in shares of Establishment Labs by 29.3% in the fourth quarter. Capital Research Global Investors now owns 1,911,525 shares of the company's stock worth $88,064,000 after buying an additional 433,484 shares during the last quarter. Nantahala Capital Management LLC boosted its stake in shares of Establishment Labs by 7.2% in the first quarter. Nantahala Capital Management LLC now owns 1,774,044 shares of the company's stock worth $72,390,000 after buying an additional 119,574 shares during the last quarter. Findell Capital Management LLC boosted its stake in shares of Establishment Labs by 28.5% in the fourth quarter. Findell Capital Management LLC now owns 1,346,480 shares of the company's stock worth $62,032,000 after buying an additional 298,380 shares during the last quarter. Finally, Rice Hall James & Associates LLC boosted its stake in shares of Establishment Labs by 7.4% in the first quarter. Rice Hall James & Associates LLC now owns 827,423 shares of the company's stock worth $33,763,000 after buying an additional 56,756 shares during the last quarter. Hedge funds and other institutional investors own 72.91% of the company's stock.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.